Document Detail


A cost-effectiveness study comparing the as-needed use of formoterol (Oxis) and terbutaline (Bricanyl) in patients with moderate to severe asthma.
MedLine Citation:
PMID:  11575897     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study evaluated the economic and health-related consequences of the as-needed use of a long-acting beta2-agonist with fast onset (formoterol, Oxis Turbuhaler 4.5 microg) versus a short-acting beta2-agonist (terbutaline, Bricanyl Turbuhaler 0.5 mg) in patients with moderate to severe asthma. A multi-national (Sweden, Norway, The Netherlands and Greece), multi-centre (35 centres), randomized, double-blind clinical trial was conducted using 362 patients on inhaled steroids during a 12-week period. The effectiveness results were pooled and the total costs included estimates for beta2-agonists, inhaled steroids, oral steroids, physician visits and sick-leave. The 182 patients in the formoterol group had 14,404 days of exposure and 29 severe exacerbations, and the 180 patients in the terbutaline group had 13,655 days of exposure and 48 severe exacerbations. The terbutaline group had 62% more severe exacerbations than the formoterol group (P=0.039), based on exposure time. Per patient, the calculated total costs were SEK 3386 for the formoterol group and SEK 3709 for the terbutaline group over the 12-week period. The conclusion is that the use of Oxis Turbuhaler instead of Bricanyl Turbuhaler for as-needed treatment is a more effective treatment generating cost savings from a societal perspective.
Authors:
F Berggren; T Ekström
Related Documents :
18479627 - Comparison of drain versus no drain thyroidectomy: randomized prospective clinical trial.
18676897 - Inpatient compared with home-based rehabilitation following primary unilateral total hi...
16547617 - Thyroidectomy using monitored local or conventional general anesthesia: an analysis of ...
10561357 - Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving ...
19245287 - Long-term seizure outcome after corpus callosotomy: a retrospective analysis of 95 pati...
16962307 - Systemic corticosteroids in chronic obstructive pulmonary disease: an overview of cochr...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Respiratory medicine     Volume:  95     ISSN:  0954-6111     ISO Abbreviation:  Respir Med     Publication Date:  2001 Sep 
Date Detail:
Created Date:  2001-09-28     Completed Date:  2001-10-04     Revised Date:  2013-06-11    
Medline Journal Info:
Nlm Unique ID:  8908438     Medline TA:  Respir Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  753-8     Citation Subset:  IM    
Affiliation:
AstraZeneca R&D Lund, and Lund University Centre for Health Economics, Sweden. Fredrik.Berggren@astrazeneca.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Anti-Asthmatic Agents / administration & dosage*,  economics
Asthma / drug therapy*,  economics
Confidence Intervals
Cost Savings
Cost of Illness
Cost-Benefit Analysis
Double-Blind Method
Ethanolamines / administration & dosage*,  economics
Female
Humans
Male
Middle Aged
Poisson Distribution
Terbutaline / administration & dosage*,  economics
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Asthmatic Agents; 0/Ethanolamines; 23031-25-6/Terbutaline; 5ZZ84GCW8B/formoterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevalence of obstructive lung diseases and respiratory symptoms in relation to living environment a...
Next Document:  Screening of obstructive sleep apnoea: heart rate spectral analysis of nocturnal pulse oximetric rec...